386 results match your criteria: "Switzerland P.K.; and Centre d'Imagerie Medicale de l'Ouest Parisien[Affiliation]"
Microorganisms
July 2024
Takeda Pharmaceutical Company Limited, Osaka 541-0045, Japan.
We previously reported the first-in-human assessment of three doses (2, 5, and 10 µg) of purified inactivated Zika virus vaccine (PIZV or TAK-426) in the Phase 1 ZIK-101 study (NCT03343626). Here, we report dose selection based on extended safety and immunogenicity data (6 months post-vaccination) and discuss considerations (e.g.
View Article and Find Full Text PDFFertil Steril
December 2024
Department of Gynecology Obstetrics and Neonatology, General Faculty Hospital and 1st Faculty of Medicine in Prague, Prague, Czechia.
Hypertension
September 2024
Division of Cardiovascular Medicine, British Heart Foundation Centre of Research Excellence, Radcliffe Department of Medicine (Y.D., G.D., K.M.C., S.C.).
Background: Folate intake during pregnancy is essential for fetal development and maternal health. However, the specific effects of folic acid (FA) and 5-methyl-(6S)-tetrahydrofolate (5-MTHF) on the prevention and treatment of hypertensive disorders of pregnancy remain unclear. We investigated whether FA and 5-MTHF have different effects on endothelial cell tetrahydrobiopterin (BH4) metabolism in pregnancy and the possible consequences for endothelial NO generation, maternal blood pressure, and fetal growth.
View Article and Find Full Text PDFDrug Saf
October 2024
School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
Background: Pregnant persons are susceptible to significant complications following COVID-19, even death. However, worldwide COVID-19 vaccination coverage during pregnancy remains suboptimal.
Objective: This study assessed the safety and effectiveness of COVID-19 vaccines administered to pregnant persons and shared this evidence via an interactive online website.
Am J Ophthalmol
December 2024
From the European Retinoblastoma Imaging Collaboration (ERIC) (C.M.d.B., R.W.J., M.K., S.S., P.M., P.G., S.G., P.d.G., M.C.d.J.); Cancer Center Amsterdam, Imaging and Biomarkers (C.M.d.B., R.W.J., J.d.H., A.C.M., P.d.G., M.C.d.J.), Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam (C.M.d.B., R.W.J., J.d.H., P.d.G., M.C.d.J.), Amsterdam, the Netherlands.
Purpose: To evaluate the effectiveness of baseline screening and follow-up with magnetic resonance imaging (MRI) for detecting trilateral retinoblastoma (TRb) and assessing the risk of TRb development.
Design: Prospective multicenter cohort study.
Methods: A total of 607 retinoblastoma patients from 2012 through 2022 were included and followed up until September 1, 2023.
Neurol Neuroimmunol Neuroinflamm
September 2024
From the Service of Neurology (J.C.B., R.A.D.P., R.B.-V.), Department of Clinical Neurosciences, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and University of Lausanne, Switzerland; Regional Multiple Sclerosis Center (N.N.D.R.), ASST-Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology St. Josef-Hospital (R.G., I.A.), Ruhr University Bochum, Germany; Centre Hospitalier Régional Universitaire de Tours (A.M.), Hôpital Bretonneau, Service de neurologie, Tours, France; Department of Neurology (M.K.), Alfried Krupp von Bohlen und Halbach Hospital, Essen; Department of Neurology (M.K.), Medical Faculty, Heinrich Heine University of Düsseldorf, Germany; Neurology Department (L.R.-P.), Multiple Sclerosis Unit, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain; Department of Neurology (T.M.), Tohoku University Hospital, Japan; Service de Neurologie (J.-C.O.), Pôle des Neurosciences Cliniques, CHU de Bordeaux Pellegrin Tripode; Service de Neurologie et Unité Neurovasculaire (M.P.G.), Centre Hospitalier Régional d'Orléans, France; Unit of Neuroradiology (S.G.), Papa Giovanni XXIII Hospital, Bergamo, Italy; Multiple Sclerosis Center (C.B.), Second Department of Neurology, Aristotle University of Thessaloniki, Greece; Servicio de Neurología (R.P.M.), Hospital Universitario Clínico San Cecilio, Granada, Spain; Department of Neurology (B.V., I.J.), University Hospital Zurich and University of Zurich, ; Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience (P.K., T.J.D.), Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Switzerland; Service de Neurologie (X.M.), Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol; Infectious and Tropical Diseases Unit (G.M.-B.), University Hospital of Toulouse, France; Department of Neurology (C.M.), State University of New York Upstate Medical University, Syracuse; and CHU Nantes (D.A.L.), Service de Neurologie, CRC-SEP, Nantes Université, INSERM, CIC 1413, Center for Research in Transplantation and Translational Immunology, UMR 1064, France.
Background And Objectives: Progressive multifocal leukoencephalopathy (PML) is a severe neurologic disease resulting from JC virus reactivation in immunocompromised patients. Certain multiple sclerosis (MS) disease-modifying therapies (DMTs) are associated with PML risk, such as natalizumab and, more rarely, sphingosine-1-phosphate receptor modulators (S1P-RMs). Although natalizumab-associated PML is well documented, information on S1P-RM-associated PML is limited.
View Article and Find Full Text PDFAJNR Am J Neuroradiol
July 2024
Division of Diagnostic and Therapeutic Neuroradiology, Department of Radiology, St. Michael's Hospital (J.D.B.D., N.M.C., J.S., V.M.P., A.A.D.), University of Toronto, Toronto, Ontario, Canada
Nat Commun
June 2024
Department of Biochemistry, University of Washington, Seattle, Washington, USA.
JACC Adv
February 2024
Department of Medicine I, Division Thrombosis & Hemostasis, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
Background: Treatment with vitamin K antagonists (VKAs) has been linked to worsening of kidney function in patients with atrial fibrillation (AF).
Objectives: XARENO (Factor XA-inhibition in RENal patients with non-valvular atrial fibrillation Observational registry; NCT02663076) is a prospective observational study comparing adverse kidney outcomes in patients with AF and advanced chronic kidney disease receiving rivaroxaban or VKA.
Methods: Patients with AF and an estimated glomerular filtration rate (eGFR) of 15 to 49 mL/min/1.
Europace
July 2024
Department of Cardiology, University Hospital Basel, University of Basel, Petersgraben 4, 4031 Basel, Switzerland.
Stroke
August 2024
Department of Neurology and Rehabilitation Medicine (E.A.M., B.M.K., K.S.A., S.F., S.L.D., M.H., D.W., Y.N.A., P.K.), University of Cincinnati, OH.
Background: As stroke endovascular thrombectomy (EVT) treatment indications expand, understanding population-based EVT eligibility becomes critical for resource planning. We aimed to project current and future population-based EVT eligibility in the United States.
Methods: We conducted a post hoc analysis of the physician-adjudicated GCNKSS (Greater Cincinnati Northern Kentucky Stroke Study; 2015 epoch), a population-based, cross sectional, observational study of stroke incidence, treatment, and outcomes across a 5-county region.
Brain Sci
June 2024
Department of Neuroradiology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Cerebral intraparenchymal hemorrhage due to electrode implantation (CIPHEI) is a rare but serious complication of deep brain stimulation (DBS) surgery. This study retrospectively investigated a large single-center cohort of DBS implantations to calculate the frequency of CIPHEI and identify patient- and procedure-related risk factors for CIPHEI and their potential interactions. We analyzed all DBS implantations between January 2013 and December 2021 in a generalized linear model for binomial responses using bias reduction to account for sparse sampling of CIPHEIs.
View Article and Find Full Text PDFNeuro Oncol
October 2024
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Leptomeningeal metastases (LM) are increasingly becoming recognized as a treatable, yet generally incurable, complication of advanced cancer. As modern cancer therapeutics have prolonged the lives of patients with metastatic cancer, specifically in patients with parenchymal brain metastases, treatment options, and clinical research protocols for patients with LM from solid tumors have similarly evolved to improve survival within specific populations. Recent expansions in clinical investigation, early diagnosis, and drug development have given rise to new unanswered questions.
View Article and Find Full Text PDFJ Clin Epidemiol
September 2024
Meta-Research Innovation Center at Stanford, Stanford University, Stanford, CA, USA; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine (Stanford Prevention Research Center), Stanford University School of Medicine, Stanford, CA, USA; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA; Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, CA, USA. Electronic address:
J Sleep Res
February 2025
Centre National de Référence Narcolepsie, Unité du Sommeil, CHU Montpellier, Hôpital Gui-de-Chauliac, Université de Montpellier, INSERM INM, Montpellier, France.
Stroke
July 2024
Department of Neurology, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA (M.F.).
Nat Catal
April 2024
Institute of Microbiology, Department of Biology, ETH Zurich, Zurich, Switzerland.
Methanol synthesized from captured greenhouse gases is an emerging renewable feedstock with great potential for bioproduction. Recent research has raised the prospect of methanol bioconversion to value-added products using synthetic methylotrophic , as its metabolism can be rewired to enable growth solely on the reduced one-carbon compound. Here we describe the generation of an strain that grows on methanol at a doubling time of 4.
View Article and Find Full Text PDFEur Heart J Case Rep
May 2024
Department of Cardiology and Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.
Background: Differentiation of syncope from seizure is challenging and has therapeutic implications. Cardioinhibitory reflex syncope typically affects young patients where permanent pacing should be avoided whenever possible. Cardioneuroablation may obviate the need for a pacemaker in well-selected patients.
View Article and Find Full Text PDFJ Clin Med
May 2024
Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland, 6900 Lugano, Switzerland.
Cannabinoid oro-mucosal spray nabiximols is approved for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to other antispastic medications. Few real-world data are available on the effectiveness, safety and patients' satisfaction in MS patients treated with nabiximols as monotherapy. To investigate the effectiveness, tolerability and satisfaction of nabiximols in a real-life multicentric Swiss cohort as monotherapy or with stable doses of other antispastic medications, and explore clinical features which may predict treatment response.
View Article and Find Full Text PDFStroke
July 2024
Environment & Health Modelling (EHM) Lab, Department of Public Health Environments and Society (A.G.), London School of Hygiene & Tropical Medicine, United Kingdom.
Background: Extreme temperatures contribute significantly to global mortality. While previous studies on temperature and stroke-specific outcomes presented conflicting results, these studies were predominantly limited to single-city or single-country analyses. Their findings are difficult to synthesize due to variations in methodologies and exposure definitions.
View Article and Find Full Text PDFCirculation
July 2024
Department of Neurology (M.B.G., S.A., T.H., U.F.), Inselspital Bern University Hospital and University of Bern, Switzerland.
Background: Whether hemorrhagic transformation (HT) modifies the treatment effect of early compared with late initiation of direct oral anticoagulation in people with ischemic stroke and atrial fibrillation is unknown.
Methods: This is a post hoc analysis of the ELAN trial (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation). The primary outcome was a composite of recurrent ischemic stroke, symptomatic intracranial hemorrhage, major extracranial bleeding, systemic embolism, or vascular death within 30 days.
Stroke
July 2024
Radiology (M.M.Q., M.A., P.K., J.B., T.N.N.), Boston Medical Center, MA.
Background: Studies comparing bridging intravenous thrombolysis (IVT) with direct endovascular therapy (EVT) in patients with acute ischemic stroke who present late are limited. We aimed to compare the clinical outcomes and safety of bridging IVT in patients with acute ischemic stroke due to anterior circulation large vessel occlusion who underwent EVT 6 to 24 hours after time last known well.
Methods: We enrolled patients with anterior circulation large vessel occlusion stroke and a National Institutes of Health Stroke Scale score of ≥6 from 20 centers across 10 countries in the multicenter retrospective CLEAR study (CT for Late Endovascular Reperfusion) between January 2014 and May 2022.
Neurology
May 2024
From the Department of Neurology (T.N.N., P.K., Z.M.), and Department of Radiology (T.N.N., M.M.Q., M.A., P.K., Z.M.), Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, MA; Department of Neurology (R.G.N.), Neurosurgery, University of Pittsburgh Medical Center, PA; Department of Radiation Oncology (M.M.Q.), Boston Medical Center, MA; Department of Neurology (S. Nagel), Klinikum Ludwigshafen, Ludwigshafen, Germany; Department of Neurology (S. Nagel, P.A.R.), Heidelberg University Hospital, Germany; Interventional Neuroradiology Laboratory (J.R., D.R.), Department of Radiology, Centre Hospitalier de l'Universite de Montreal, Quebec, Canada; Department of Neurology (J.D., L.V., A.W., R.L.), UZ Leuven; Laboratory for Neurobiology (J.D., L.V., A.W., R.L.), KU Leuven, Belgium; Department of Neurology (J.P.M., R.V.), Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Portugal; Department of Neurology (S.A.S., S.S.-M.), UTHealth McGovern Medical School, Houston, TX; Department of Neurology (V.P., S.W.), and Dresden Neurovascular Center (V.P., S.W., D.P.O.K.), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Department of Neurology (A.D., F.B.), Hôpital Civil Marie Curie, Charleroi, Belgium; Department of Neurology (P.M., D. Strambo), Lausanne University Hospital and University of Lausanne, Switzerland; Department of Neurology (M. Ribo, M.O.-G., M. Requena), Hospital Vall d'Hebron, Barcelona, Spain; Neuroscience and Stroke Program (O.O.Z., E.L.), Bon Secours Mercy Health St. Vincent Hospital, Toledo, OH; Department of Neurology (J.E.S.), University of Chicago, IL; Department of Neurology (D.C.H., M.H.M.), Grady Memorial Hospital, Atlanta, GA; Department of Neurology (D. Strbian, L.T., N.M.-M.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neurology (H.H., F.C., C.C.), Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France; Department of Radiology (M.A.M., J.J.), Heidelberg University Hospital, Germany; Division of Interventional Neuroradiology (A.S.P.), University of Massachusetts Memorial Medical Center, Worcester; Department of Diagnostic and Interventional Neuroradiology (J.K., A.M.), University Hospital Bern, Switzerland; Department of Radiology (J.N.R.), Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Portugal; Department of Neurology (M.A.J., S.F.Z., A.C.C.), University of Toledo, OH; Department of Clinical Neurosciences (S. Nannoni), University of Cambridge, United Kingdom; Department of Neurology (M.F., S.O.-G.), University of Iowa, Iowa City; Department of Radiology (P.V., E.P.), Helsinki University Hospital, University of Helsinki, Finland; Institute of Neuroradiology (D.P.O.K.), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Department of Neurology (L.S., S.Y.), Rhode Island Hospital, Providence; Department of Neurology (Z.Q.), 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China; Department of Neurology (H.E.M.), State University of New York, Syracuse; Department of Neurology (W.H.), The First Affiliated Hospital of USTC, China; Department of Cerebrovascular Medicine (K.T.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Stroke Neurology (H.Y.), NHO Osaka National Hospital, Japan; Department of Neurology (U.F.), University Hospital Basel, Switzerland; Department of Neurology (U.F.), University Hospital Bern, Switzerland; and Department of Neurology (T.G.J.), Cooper University Hospital, Camden, NJ.
Background And Objectives: There is uncertainty whether patients with large vessel occlusion (LVO) presenting in the late 6-hour to 24-hour time window can be selected for endovascular therapy (EVT) by noncontrast CT (NCCT) and CT angiography (CTA) for LVO detection. We evaluated the clinical outcomes of patients selected for EVT by NCCT compared with those medically managed in the extended time window.
Methods: This multinational cohort study was conducted at 66 sites across 10 countries.